Trial reportAlimentary pharmacology & therapeutics2022
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.
Trial report in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 69 citations in OpenAlex.
- The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis.Hepatology (Baltimore, Md.) · 2026Trial
- OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers.Clinical drug investigation · 2023Trial
- Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.Alimentary pharmacology & therapeutics · 2022Trial
- Albumin in the Management of Hepatorenal Syndrome-Acute Kidney Injury: Is There Ever Too Much?Digestive diseases and sciences · 2026Article
- Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).Pediatric nephrology (Berlin, Germany) · 2026Review
- Critical care hepatology: A narrative review of current concepts and management.World journal of critical care medicine · 2026Review
- Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease.Diagnostics (Basel, Switzerland) · 2026Review
- United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injury.JHEP reports : innovation in hepatology · 2026Article
- A retrospective study on the use of albumin in the management of complications of decompensated cirrhosis from a major teaching hospital in Canada.Canadian liver journal · 2025Article
- Acute-on-chronic liver failure.BJA education · 2025Review
- Use of Terlipressin in Liver Transplant Candidates.Gastroenterology & hepatology · 2025Article
- Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging.JHEP reports : innovation in hepatology · 2025Article
- From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.Hepatology (Baltimore, Md.) · 2025Review
- Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis.Intensive care medicine · 2025Article
- Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis. Author's reply.Intensive care medicine · 2025Article
- Terlipressin use in HRS-AKI and respiratory failure.Intensive care medicine · 2024Article
- Review
- Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis.Journal of clinical medicine · 2023Review
- Formulary Drug Reviews: Terlipressin.Hospital pharmacy · 2023Review
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies suggested increased mortality in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute-on-chronic liver failure (ACLF).
aimTo assess mortality and respiratory failure (RF) in patients with HRS1 and ACLF treated with terlipressin.
methodsIn the CONFIRM study, we randomised 299 patients with HRS1 2:1 to terlipressin or placebo, both with albumin. At enrolment, all patients were assessed for organ failure (OF) using a validated ACLF grading system. Post hoc analyses assessed the effects of terlipressin vs. placebo on the incidence of RF and 90-day mortality.
resultsThe incidence of RF with terlipressin (n = 200) was 9.4% in patients with grades 1-2 ACLF, and 30% with grade 3 ACLF (p = 0.0002); no such difference was observed in placebo-treated patients (n = 99) (6.2% grades 1-2 vs. 0% grade 3 ACLF, p > 0.05). RF incidence between terlipressin and placebo in patients with grade 3 ACLF was significant (p = 0.01). Baseline predictors of RF with terlipressin were INR (p = 0.011), mean arterial pressure (p = 0.037), and SpO
conclusionTerlipressin should be used with caution in patients with HRS1 and grade 3 ACLF. Patients with hypoxaemia are at increased risk of RF and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.